Observable changes typically emerge 8–16 weeks post-infusion and may continue to improve over 6–12 months. Durability beyond 12 months is incompletely characterised; a few families report sustained gains years later, but systematic follow-up is sparse. Unlike acute neuroprotective effects, developmental gains likely depend on ongoing neural plasticity and environmental support (education, therapy). Repeat infusions may be needed to sustain or amplify benefit, but protocols are not standardised.
Developmental cognitive delay encompasses intellectual disabilities arising from prenatal, perinatal, or early postnatal injury or genetic factors. Stem cell research in this field concentrates on neurogenic cells—progenitors capable of differentiating into neurons and supporting glial cells—and placental mesenchymal stem cells (MSCs), which secrete neuroprotective factors. The therapeutic rationale rests on replacing damaged neural tissue and reducing neuroinflammation in developing brains. Neurogenic cells, often derived from foetal sources or reprogrammed from adult tissue, may promote rewiring of neural circuits impaired by anoxia, infection, or genetic dysgenesis. Placental MSCs offer an allogeneic, non-invasive source with immunomodulatory properties. Two registered trials and one actively recruiting study are currently investigating safety and functional outcomes in paediatric populations.
האם אני מועמד? → · Developmental Cognitive Delay: full overview → · עלות השהיית התפתחות קוגניטיבית → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם